Penn Pharma To Expand High Containment Ops

Penn Pharma will invest $22 million in its South Wales, UK facility to expand its high containment facilities with a 15,000-sq.-ft. new development and commercial manufacturing unit for tablets and
capsules.

Penn Pharma’s chief executive officer, Dr. Richard Yarwood, said, “We are delighted to announce this significant investment in the UK pharmaceutical manufacturing sector at a time when the established industry remodels itself and outsourcing is on the increase. This investment is the catalyst required to enable us to build on the services that we are currently offering our clients and ensure that we are able to react to the evolving market place. We have seen a growth in the number of highly potent compounds coming through the pharmaceutical early phase pipeline and in response to this we are investing in an expansion of our existing resources to meet this growing demand.”

The company received additional funding and training support from the Welsh Assembly Government.